Recurring Brain Tumors Follow Distinct Genetic Paths, Global Study Finds

For patients diagnosed with certain brain tumors, one of the most difficult questions is not what will happen at diagnosis, but what will happen when the cancer comes back. IDH-mutant gliomas, a group of brain tumors defined by mutations in a gene called isocitrate dehydrogenase, almost invariably recur despite years of therapeutic progress. A new international study has now traced, in unprecedented detail, the genetic transformations these tumors undergo between initial treatment and recurrence, offering some of the clearest evidence yet about why they so often outlast current therapies.

The research, published in Nature, was led by scientists from The Jackson Laboratory, Yale University, and collaborators spanning ten countries. Drawing on data from the international Glioma Longitudinal Analysis Consortium, known as GLASS, the team analyzed tumors from 183 patients whose cancers were sampled both before treatment and again after recurrence. The samples were collected through more than 500 surgeries performed across North America, Europe, Asia, Australia and South America, allowing researchers to directly compare how the same tumors changed over time within individual patients.

The scale of the effort matters because IDH-mutant gliomas are rare. Individual institutions rarely accumulate enough paired samples to draw statistically meaningful conclusions about how these tumors evolve. “IDH-mutant gliomas are rare, which makes them challenging to study. Through this international collaboration, we were able to gather enough samples to characterize the most common ways each type of IDH-mutant glioma changes when it recurs,” said study author Frederick Varn, a JAX assistant professor who co-led the research. By pooling tumors from dozens of centers, the consortium could identify recurring patterns of evolution rather than isolated case anecdotes.

IDH-mutant gliomas primarily strike patients in their 30s and 40s, an age group in which a brain cancer diagnosis is particularly devastating. Although many patients live for years after diagnosis, these tumors almost always return, and when they do, they tend to stop responding to the treatments that initially held them in check. Understanding the genetic events that accompany that transition has been a central goal of the neuro-oncology field, because it may reveal vulnerabilities that could be targeted before resistance becomes entrenched.

The most striking findings emerged from comparing the two main subtypes of IDH-mutant glioma: oligodendroglioma and astrocytoma. Although both are defined by the same IDH mutation, the study showed that they follow sharply divergent evolutionary paths after treatment. Oligodendrogliomas tended to acquire new point mutations in genes that help drive tumor growth, adding fresh genetic damage one alteration at a time. Astrocytomas, by contrast, were far more likely to undergo large-scale chromosomal events, gaining and losing entire stretches of DNA as the disease progressed.

“Oligodendroglioma and astrocytoma are distinct tumor types, despite sharing the IDH mutation. This study shows that differences that exist when the tumor is first detected can set the stage for what happens after they are treated,” Varn said. In other words, the biology a tumor carries at diagnosis appears to shape the menu of evolutionary strategies available to it later. A tumor’s starting genome, in this view, is not merely a snapshot of its present state but a forecast of how it will respond to the selective pressures of therapy.

The treatment itself also left measurable marks. The chemotherapy drug temozolomide, a standard therapy for these tumors, appeared to leave distinct genetic fingerprints in recurrent tumors, a signature pattern of mutations that researchers could detect in the post-treatment samples. This observation underscores a growing theme in cancer genomics: therapy is not a neutral event but an evolutionary force, and the drugs used to control a tumor can actively shape the genetic changes it acquires as it fights back.

Crucially, some of the genetic changes observed at recurrence were associated with worse outcomes for patients. In astrocytomas, large-scale chromosomal abnormalities, including the duplication of entire sets of chromosomes and catastrophic events in which chromosomes broke apart and reassembled, were linked to shorter survival after recurrence. In oligodendrogliomas, new genetic changes that emerged as tumors returned, including alterations linked to uncontrolled cell growth, were likewise associated with poorer prognosis. These associations suggest that the mode of evolution is not just biologically interesting but clinically meaningful, potentially helping physicians identify which patients face the greatest risk once their disease returns.

The findings arrive at a moment of real momentum for the field. In 2024, the FDA approved vorasidenib, an IDH inhibitor, for certain patients with these tumors, marking a major therapeutic advance. While the new study focused specifically on the changes tumors undergo after radiation and chemotherapy rather than after IDH inhibition, its results can be applied to tailor treatment approaches to specific glioma types and to the genetic changes each type is likely to acquire as it evolves. A clinician who knows that an astrocytoma is prone to wholesale chromosomal upheaval, for example, may monitor and treat it differently than one facing an oligodendroglioma that accumulates targeted mutations.

“Our results and datasets provide a reference that helps understand how current and new therapies alter tumor behavior. Ultimately, we hope this will enable us to not just observe but to direct tumor behavior and make therapies more effective that way,” said Roel Verhaak, Ph.D., vice chair for research and professor of neurosurgery at Yale School of Medicine. That ambition, steering tumor evolution rather than merely documenting it, represents a shift in how researchers think about treating cancers that recur. The study was conducted through the GLASS Consortium with researchers from institutions across North America, Europe, Asia and Australia, and was funded by the National Institutes of Health along with additional public, philanthropic and institutional sources. For patients facing a disease that almost always returns, the work offers something concrete: a genetic map of what recurrence actually looks like, and a foundation for anticipating it.

Subject of Research: Genomic evolution of recurrent IDH-mutant gliomas

Article Title: What happens when brain tumors return? International study tracks genetic changes behind recurring cancers

Article References: What happens when brain tumors return? International study tracks genetic changes behind recurring cancers. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: glioma, IDH mutation, astrocytoma, oligodendroglioma, tumor recurrence, genomic evolution, temozolomide, GLASS Consortium, Jackson Laboratory, Yale University, Nature, treatment resistance